[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562755":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":7,"locations":8,"responsibleParty":29,"collaborators":7,"id":31,"slug":32,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":35,"acronym":7,"eligibilityCriteria":36,"healthyVolunteers":33,"sex":37,"minAge":7,"maxAge":7,"enrollmentInfo":38,"targetDuration":7,"studyType":41,"phases":7,"briefSummary":42,"conditions":43,"keywords":45,"overallStatus":11,"whyStopped":7,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":57},{"fullName":5,"class":6},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",null,[9],{"facility":10,"status":11,"city":12,"state":13,"zip":14,"country":15,"countryCode":16,"cosmosGeoPoint":17,"geoPoint":22,"contacts":23},"Institute of Hematology & Blood Diseases Hospital","RECRUITING","Tianjin","Tianjin Municipality","300000","China","CN",{"type":18,"coordinates":19},"Point",[20,21],117.17667,39.14222,{"lat":21,"lon":20},[24],{"name":25,"role":26,"phone":27,"phoneExt":7,"email":28},"Zhen Song, MD","CONTACT","+86 02223909051","cir@ihcams.ac.cn",{"type":30,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100562755","national-longitudinal-cohort-of-hematological-diseases-niche---cart-100562755",false,"NCT06607289","National Longitudinal Cohort of Hematological Diseases (NICHE) - CART","Inclusion Criteria:\n\n* Patients with clinically diagnosed hematologic malignancies\n* Patients treated with CAR-T cell therapy\n* Signed the informed consent form","ALL",{"count":39,"type":40},1000,"ESTIMATED","OBSERVATIONAL","This is a multicenter, ambispective, longitudinal, observational cohort study investigating CAR-T cell therapy in Chinese patients with hematological malignancies. A consortium of Phase IV clinical trials and real-world studies of Chimeric antigen receptors (CAR) T cell therapy will be established in China. Patient-level data from these studies will be collected to create a large real-world cohort. In addition, patients receiving CAR-T cell therapy for hematological malignancies identified from an existing hematology longitudinal cohort study, the National Longitudinal Cohort of Hematological Diseases (NICHE), will also be included in the study.",[44],"Hematological Malignancies",[46,47],"Chimeric antigen receptors (CAR) T cell","hematological malignancies","2025-06-15",{"date":50,"type":51},"2025-06-17","ACTUAL",{"date":53,"type":51},"2021-06-01",{"date":55,"type":40},"2032-12-31",{"name":5,"class":6},1]